What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The clinical trial evidence shows that upadacitinib significantly increases the likelihood of disease remission compared to placebo, with statistically significant improvements in clinical remission and endoscopic response in the biological failure population. The indirect comparisons via network meta-analyses suggest that upadacitinib has similar efficacy to ustekinumab and vedolizumab, which supports its clinical effectiveness.
Does the economic case hold at the expected price? — Cost effectiveness
The cost comparison indicates that upadacitinib has a similar or lower cost than existing treatments like ustekinumab and vedolizumab, which supports its cost-effectiveness. The committee concluded that the overall health benefits are comparable, justifying its recommendation.
Is there quality-of-life evidence payers weigh? — Quality of life
While specific HRQoL data is not detailed in the document, the overall improvement in clinical outcomes and the acknowledgment of the profound impact of Crohn’s disease on patients’ lives suggest that upadacitinib likely provides moderate improvements in quality of life, particularly for those who have not responded to other treatments.
Does the safety profile hold up for payers? — Safety and Adverse Effects
The safety analysis indicates that serious adverse events are comparable between upadacitinib and its comparators, with low discontinuation rates due to adverse events. This suggests an acceptable safety profile, although some concerns regarding specific populations were noted.
Was the drug compared against what payers expect? — Comparator Selection
The document discusses appropriate comparators, including ustekinumab and vedolizumab, which are standard treatments for Crohn’s disease. The committee’s conclusion that these are relevant comparators supports the robustness of the evidence.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trials included a relevant patient population, particularly those with biological failure, which aligns with the intended use of upadacitinib. However, there are some limitations in subgroup analyses that could affect generalizability.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Upadacitinib is an oral treatment, which is a significant advantage over other therapies that may require injections. This suggests a minor adjustment in care pathways, making integration manageable.
Are the wider system costs understood? — Resource Use and Cost Implications
The document indicates that the budget impact of upadacitinib is manageable and aligns with planning, given its similar or lower costs compared to existing treatments. This suggests a justifiable resource use.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence is based on multiple clinical trials and network meta-analyses, which provide a strong foundation. However, some limitations in the data and the reliance on indirect comparisons introduce some concerns.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
While there are some uncertainties regarding the long-term outcomes and specific population risks, the overall context of unmet need and the potential benefits of additional treatment options mitigate these concerns.
